No Data
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective Anti-CCR8 Cytolytic Antibody
H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7
Analysts Conflicted on These Healthcare Names: Coherus Biosciences (CHRS), EDAP TMS (EDAP) and ATyr Pharma (ATYR)
Coherus Oncology Inc (CHRS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ...
Coherus Oncology | 10-Q: Q3 2025 Earnings Report
Coherus Oncology | 8-K: Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update